Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Egyptian adults

Journal of Infectious Diseases

Volumn 177, Issue 3, 1998, Pages 796-799

  Savarino, Stephen J ^a   Brown, F Matthew ^b   Hall, Eric ^c   Bassily, Samir ^c   Youssef, Fouad ^c   Wierzba, Thomas ^c   Peruski, Leonard ^c   Ei Masry, Nabil A ^c   Safwat, Mohammed ^c   Rao, Malla ^c   Jertborn, Marianne ^c   Svennerholm, Ann Mari ^c   Lee, Young J ^c   Clemens, John D ^c  

^a US Naval Medical Research Unit No 3

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CHOLERA TOXIN B SUBUNIT; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN A; PLACEBO;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG SAFETY; EGYPT; ENTEROBACTER INFECTION; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION PREVENTION; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 17344368197     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517812     Document Type: Article

References (11)

1. Svennerholm AM, Holmgren J, Sack DA. Development of oral vaccines against enterotoxigenic Escherichia coli diarrhoea. Vaccine 1989;7: 196-8.
2. Czerkinsky C, Svennerholm AM, Holmgren J. Induction and assessment of immunity at enteromucosal surfaces in humans: implications for vaccine development. Clin Infect Dis 1993;16(SuppI 2):S106-16.
3. Ahren CM, Svennerholm AML. Synergistic protective effect of antibodies against Escherichia coli enterotoxin and colonization factor antigens. Infect Immun 1982;38:74-9.
4. Clemens JD, Sack DA, Harris JR, et al. Cross-protection by B subunitwhole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 1988;158:372-7.
5. Peltola H, Siitonen A, Kyronseppa H, et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991;338: 1285-9.
6. Ahren C, Wenneras C, Holmgren J, Svennerholm AM. Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. Vaccine 1993;11:929-34.
7. Wenneras C, Svennerholm AM, Ahren C, Czerkinsky C. Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. Infect Immun 1992;60:2605-11.
8. 7a.Jertborn M, Ahren C, Holmgren J, Svennerholm AM. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli vaccine. Vaccine 1998;16:255-60.
9. Zaki AM, Dupont HL, El Alamy MA, et al. The detection of enteropathogens in acute diarrhea in a family cohort population in rural Egypt. Am J Trop Med Hyg 1986;35:1013-22.
10. Czerkinsky C, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983;65: 109-21.
11. Svennerholm AM, Holmgren J. Identification of Escherichia coli heatlabile enterotoxin by means of a ganglioside immunosorbent assay (GM1-ELISA) procedure. Curr Microbiol 1978;1:19-23.